MA71371A - Modulateurs de trem2 - Google Patents
Modulateurs de trem2Info
- Publication number
- MA71371A MA71371A MA71371A MA71371A MA71371A MA 71371 A MA71371 A MA 71371A MA 71371 A MA71371 A MA 71371A MA 71371 A MA71371 A MA 71371A MA 71371 A MA71371 A MA 71371A
- Authority
- MA
- Morocco
- Prior art keywords
- trem2
- modulators
- trem2 modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22182841 | 2022-07-04 | ||
| EP22196374 | 2022-09-19 | ||
| EP22211409 | 2022-12-05 | ||
| EP22215488 | 2022-12-21 | ||
| EP23154600 | 2023-02-02 | ||
| EP23164257 | 2023-03-27 | ||
| EP23169796 | 2023-04-25 | ||
| EP23172505 | 2023-05-10 | ||
| EP23738520.8A EP4551575A2 (fr) | 2022-07-04 | 2023-07-04 | Modulateurs de trem2 |
| PCT/EP2023/068406 WO2024008722A2 (fr) | 2022-07-04 | 2023-07-04 | Modulateurs de trem2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71371A true MA71371A (fr) | 2025-04-30 |
Family
ID=87155582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71371A MA71371A (fr) | 2022-07-04 | 2023-07-04 | Modulateurs de trem2 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4551575A2 (fr) |
| JP (1) | JP2025521856A (fr) |
| KR (1) | KR20250029045A (fr) |
| CN (1) | CN119403806A (fr) |
| AU (1) | AU2023303060A1 (fr) |
| CA (1) | CA3256281A1 (fr) |
| IL (1) | IL317435A (fr) |
| MA (1) | MA71371A (fr) |
| MX (1) | MX2024015708A (fr) |
| WO (1) | WO2024008722A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023086799A1 (fr) * | 2021-11-09 | 2023-05-19 | Vigil Neuroscience, Inc. | Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 |
| CN121194974A (zh) * | 2023-05-30 | 2025-12-23 | 豪夫迈·罗氏有限公司 | Trem2激动剂 |
| TW202535410A (zh) * | 2024-01-04 | 2025-09-16 | 丹麥商穆納醫療有限責任公司 | Ｔｒｅｍ２調節劑 |
| WO2025146476A1 (fr) * | 2024-01-04 | 2025-07-10 | Muna Therapeutics Aps | Dérivés de 2-(tétrahydro-2 h-pyran-4-yl)-7-méthyl-8-oxo-6-(trifluorométhyl)-7,8-dihydropyrimido[5,4-d]pyrimidine utilisés en tant que modulateurs de trem2 pour le traitement de maladies neurodégénératives |
| WO2025146477A1 (fr) | 2024-01-04 | 2025-07-10 | Muna Therapeutics Aps | Dérivés de 2-azétidinyl-7-méthyl-8-oxo-6-(trifluorométhyl)-7,8-dihydropyrimido[5,4-d] pyrimidine utilisés en tant que modulateurs de trem2 pour le traitement de maladies neurodégénératives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2846657B1 (fr) * | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20210122746A1 (en) * | 2017-12-02 | 2021-04-29 | Bristol-Myers Squibb Company | Febrifugine derivatives |
| US20220089609A1 (en) * | 2018-07-26 | 2022-03-24 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| US20210163443A1 (en) * | 2019-12-02 | 2021-06-03 | Bristol-Myers Squibb Company | Febrifugine Derivatives |
| JP7639020B2 (ja) * | 2020-04-17 | 2025-03-04 | ドン－ア エスティ カンパニー リミテッド | アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用 |
| BR112022022338A2 (pt) * | 2020-05-04 | 2023-01-10 | Amgen Inc | Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso |
-
2023
- 2023-07-04 KR KR1020247040987A patent/KR20250029045A/ko active Pending
- 2023-07-04 CA CA3256281A patent/CA3256281A1/fr active Pending
- 2023-07-04 MA MA71371A patent/MA71371A/fr unknown
- 2023-07-04 WO PCT/EP2023/068406 patent/WO2024008722A2/fr not_active Ceased
- 2023-07-04 IL IL317435A patent/IL317435A/en unknown
- 2023-07-04 EP EP23738520.8A patent/EP4551575A2/fr active Pending
- 2023-07-04 CN CN202380048370.XA patent/CN119403806A/zh active Pending
- 2023-07-04 AU AU2023303060A patent/AU2023303060A1/en active Pending
- 2023-07-04 JP JP2024577387A patent/JP2025521856A/ja active Pending
-
2024
- 2024-12-16 MX MX2024015708A patent/MX2024015708A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4551575A2 (fr) | 2025-05-14 |
| AU2023303060A1 (en) | 2024-11-07 |
| CN119403806A (zh) | 2025-02-07 |
| JP2025521856A (ja) | 2025-07-10 |
| IL317435A (en) | 2025-02-01 |
| MX2024015708A (es) | 2025-03-07 |
| WO2024008722A2 (fr) | 2024-01-11 |
| CA3256281A1 (fr) | 2024-01-11 |
| KR20250029045A (ko) | 2025-03-04 |
| WO2024008722A3 (fr) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71371A (fr) | Modulateurs de trem2 | |
| LT4069691T (lt) | Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai | |
| EP4362946A4 (fr) | Modulateurs de nlrp3 | |
| PT3873883T (pt) | Método de síntese | |
| PT4271672T (pt) | Compostos moduladores de glp-1r de carboxi-benzimidazol | |
| MA56115A (fr) | Composés de pyrrolidine | |
| GB202018412D0 (en) | Malt-1 modulators ii | |
| PL4117784T3 (pl) | Związki stanowiące modulator gpr52 | |
| GB2601134B (en) | Optical modulator | |
| EP4103564A4 (fr) | Modulateurs de p2x3 | |
| IL315592A (en) | Nlrp3 modulators | |
| EP4192957A4 (fr) | Modulateurs de trpml | |
| EP4121059A4 (fr) | Modulateurs de nlrp3 | |
| EP4435502A4 (fr) | Modulateur électro-optique | |
| EP4400902A4 (fr) | Modulateur électro-optique | |
| EP4025957C0 (fr) | Modulateur électro-optique | |
| EP4217346C0 (fr) | Modulateurs du nlrp3 | |
| DOP2023000241A (es) | Moduladores de trex1 | |
| EP4130278A4 (fr) | Nouvelle l-rhamnose isomérase | |
| EP3956603A4 (fr) | Convertisseur de source de lumière | |
| DOP2023000236A (es) | Moduladores de trex1 | |
| IL319101A (en) | Sortilin modulators | |
| EP4506748A4 (fr) | Modulateur électro-optique | |
| EP4426289A4 (fr) | Modulateurs d'akt3 | |
| EP4241545C0 (fr) | Bineuse universelle |